Results from a phase 2 trial, published recently in The New England Journal of Medicine, suggest that treatment with 150 mg of nintedanib slowed lung-function decline and decreased acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF), a fatal lung disease typically affecting individuals older than 50 years and characterized by worsening dyspnea and progressive loss of lung function.
A total of 1,066 subjects were involved within two replicate, 52-week, phase 3 trials, IMPULSIS-1 and IMPULSIS-2. Randomly assigned, to either nintedanib or placebo, the adjusted annual rate of change in FVC was found to be -114.7 ml with nintedanib whereas a -239.9 ml with the placebo.
Anyone looking for a detailed list of treatment options for Idiopathic Pulmonary Fibrosis should also check out the site below. It talks about the two new drugs approved, as well as other therapies. My family member that has IPF has found this site to be very helpful.
http://pulmonaryfibrosismd.com/idiopathic-pulmonary-fibrosis-treatment-options/